Precept Management LLC Savara Inc Transaction History

Precept Management LLC

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2018 Aug 14, 2018	SELL	$8.55 - $13.76 $564,300 - $908,160	-66,000 Closed	0 $0
Q1 2018 May 15, 2018	SELL	$8.99 - $14.95 $593,340 - $986,700	-66,000 Reduced 50.0%	66,000 $607,000
Q4 2017 Feb 14, 2018	BUY	$8.26 - $16.76 $454,300 - $921,800	55,000 Added 71.43%	132,000 $1.96 Million
Q3 2017 Nov 14, 2017	BUY	$5.1 - $9.55 $392,700 - $735,350	77,000	77,000 $720,000

144

147M

242K

797K

Ticker SVRA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 114,043,000
Market Cap $415M
Description
Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. Its lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase III development stage for the treatment of autoimmune pulmonary alveolar proteinosis. The company is headquartered in Austin, Texas.

Get notified when there are updates to the investment portfolio of Precept Management LLC, based on Form 13F filings with the SEC.

Stay updated on Precept Management LLC with notifications on news.